Nav: Home

FASEB Science Research Conference: Protein Kinases and Protein Phosphorylation

February 28, 2017

This conference focuses on the biology of protein kinases and phosphorylation signaling. Among FASEB's longest-running SRCs, it brings together a dynamic international community of junior investigators, trainees, and established researchers from a field that is achieving startling new insight and medical breakthroughs. The program will link detailed understanding of protein structure and biochemical mechanism to control of large-scale processes like the cell division cycle, cell morphogenesis, and metabolism.

In 1956 Krebs and Fischer demonstrated a biochemical effect of protein phosphorylation, revealing a mechanism that controls essentially all eukaryotic cell processes. Sixty years later, analysis of protein kinases and phosphorylation remains a frontier in life sciences research by seamlessly fusing structural biology, proteomics, biochemistry, systems-level cell biology, and molecular evolution. This SRC will explore the field's latest research, which is revealing surprising mechanisms of regulation, previously unappreciated subcellular organization, logic of pathways that coordinate diverse intracellular systems. Importantly, derangement of kinase signaling underlies disease, including cancer and diabetes. Drugs targeting kinases and phosphorylation have achieved dramatic cures and promise more, and the conference has consistently offered a robust platform for clinically important work. To foster international scientific connections the 2017 conference will be held at Cambridge University, a world-class academic research hub with outstanding facilities, recreational options, and social venues.

Dr. Tony Hunter, who discovered tyrosine phosphorylation and directed foundational studies of signaling mechanisms, will deliver the conference's keynote address. Platform and poster sessions will feature insights from structural and biochemical analysis, as well as emerging research in the control of cell division, metabolism, and cell architecture. The meeting will bring together scientists using a wide range of approaches, from structural biology and biochemistry to proteomics, systems biology, and cell biology. In addition to the conference's traditionally deeply ingrained focus on developing treatments for important human maladies, half of the platform sessions will have an explicit tie to clinical issues: malignancy, cancer, immunity and inflammation, and metabolic disease.
-end-


Federation of American Societies for Experimental Biology

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".